683 Capital Management, LLC Nuvation Bio Inc. Transaction History

683 Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.1 $410,164 - $683,606	-325,527 Reduced 20.67%	1,249,473 $1.67 Million
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $819,000 - $966,000	-525,000 Reduced 25.0%	1,575,000 $2.84 Million
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $640,000 - $992,000	-400,000 Reduced 16.0%	2,100,000 $3.49 Million
Q4 2022 Feb 14, 2023	SELL	$1.68 - $2.5 $134,400 - $200,000	-80,000 Reduced 3.1%	2,500,000 $4.8 Million
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $235,869 - $3.29 Million	813,343 Added 46.04%	2,580,000 $5.78 Million
Q2 2022 Aug 15, 2022	BUY	$3.24 - $5.85 $1.58 Million - $2.85 Million	486,757 Added 38.03%	1,766,657 $5.72 Million
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $4.75 Million - $9.13 Million	1,033,483 Added 419.4%	1,279,900 $6.73 Million
Q2 2021 Aug 16, 2021	SELL	$9.22 - $14.48 $3.26 Million - $5.12 Million	-353,583 Reduced 58.93%	246,417 $2.3 Million
Q1 2021 May 17, 2021	BUY	$9.0 - $14.57 $5.4 Million - $8.74 Million	600,000 New	600,000 $6.27 Million

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.